AREDS Vitamins

AREDS vitamins may have an impact on the progression of macular degeneration to the advanced stages.




Age Related Eye Disease Study

The Age Related Eye Disease Study (AREDS) is perhaps the most important study when it comes to AREDS vitamins for macular degeneration.

According to the U.S. Federal government's National Eye Institute the Age-Related Eye Disease Study found that:

"taking high levels of antioxidants and zinc can reduce the risk of developing advanced age-related macular degeneration (AMD) by about 25 percent."

"the AREDS formulation, while not a cure for AMD, may play a key role in helping people at high risk for developing advanced AMD keep their remaining vision."

Original AREDS

The specific daily amounts of antioxidants and zinc used by the study researchers were:

√ 500 milligrams of vitamin C

√ 400 International Units of vitamin E

√ 15 milligrams of beta-carotene (often labeled as equivalent to 25,000 International Units of vitamin A)

√ 80 milligrams of zinc as zinc oxide

√ 2 milligrams of copper as cupric oxide

Copper was added to the AREDS formulations containing zinc to prevent copper deficiency anemia, a condition associated with high levels of zinc intake.

AREDS 2

The Age Related Eye Disease Study 2 (AREDS 2) is a phase III study that is ongoing but it is not recruiting new participants.The estimated study completion date is June 2013.

The stated purpose is:

1) To evaluate the effect of

the two carotenoids,lutein and zeaxanthin,that accumulate in macula and

two omega-3 fatty acids (DHA and EPA) on progression to advanced age-related macular degeneration (AMD) and/or moderate vision loss in people at moderate to high risk for progression.

2) To evaluate the effects of eliminating beta-carotene from the original AREDS formulation on the development and progression of AMD.

3) To evaluate the effects of reducing zinc in the original AREDS formulation on the development and progression of AMD.

4) To contribute data for validation of the photographic AMD scales developed from the Age-Related Eye Disease Study.

Currently the National Eye Institute has recruited 4,000 participants in its Age Related Eye Disease Study 2 (AREDS).

It is designed to assess the effects of oral supplementation of high doses of the macular degeneration antioxidants, lutein and zeaxanthin, and omega-3 LCPUFAs (DHA and EPA) for the treatment of AMD and cataract.

Again this study is related to those who have been diagnosed with AMD and is not a study on the prevention of macular degeneration.

VitEyes

VitEyes uses the AREDS recommended formula without betacarotene and also includes:

1. Natural vitamin E

2. Lutein - 10 mg/day

3. Zeaxanthin - 3.5 mg/day

4. Bilberry

5. Grape seed extract, and

6. Alpha-lipoic acid.

VitEyes can be purchased from Natural Eye Care - a company that provides complementary treatment for many different eye conditions. To learn more click here:

VitEyes

ICaps Vitamins

There are three different formulas of these vitamins for eye.

1. ICaps AREDS Formula

2. ICaps Lutein and Zeaxanthin Formula and

3. ICaps Multivitamin Formula.

To learn more about what's in this vitamins and who produces them click here: Icaps Vitamins

For More Information:


Didn't find what you were looking for? Search this site by typing in a keyword and the results will be displayed below:
Loading




Go from AREDS Vitamins to Vitamins for Macular Degeneration

Go from AREDS Vitamins to WebRN Macular Degeneration Home

Would you like to be updated on:

The Latest Clinical Trials?

√ Prevention of Macular Degeneration?

√ Tips for Daily Living?

√ Food Suggestions for a Macular Degeneration Diet?

√ Ideas on Visual Aids to Maximize your Sight?

If you said "yes" to any of the above, sign up for my monthly Macular Degeneration News.

Enter your E-mail Address
Enter your First Name (optional)
Then

Don't worry -- your e-mail address is totally secure.
I promise to use it only to send you WebRN-Macular Degeneration News.

New! Comments

Share your thoughts about what you just read! Leave a comment in the box below.